St. Joe

Fairholme Capital disclosed 18,182,367 shares of St. Joe, representing 76.43% of its portfolio as of June 30, 2026, after trimming just over one million shares. St. Joe reported Q2 revenue of $158.8m, up 23% year‑over‑year, and net income of $40.5m, up 37%, with margin expansion across residential, hospitality and commercial segments. Fairholme opened small positions in Pfizer, Campbell Soup and UPS while adding to Berkshire Hathaway and Progressive; analysts warn the 76% concentration entails significant single‑name risk for retail investors. » More on finance.yahoo.com

The Fairholme Fund sold 377,800 shares of St. Joe between May 5–7, 2026 for about $24.84 million, reducing its direct position by 2.35% to 15,695,824 shares (≈$1.02 billion post-transaction). The sale was larger than most of Fairholme's recent disposals but did not involve derivatives or indirect holdings and does not signal an exit, as the fund retains roughly 75.5% of its June 2023 position. St. Joe remains a long-duration land-development play with about 170,000 acres in Northwest Florida; revenue and near-term growth are sensitive to interest rates and consumer demand, so the stock suits patient investors focused on long-term optionality rather than immediate catalysts. » More on finance.yahoo.com

St. Joe Company reports Q1 2026 revenue up 5% to USD 99.1 million, driven by a 13% increase in the hospitality segment. Net profit fell 21%, mainly due to significantly lower equity earnings from joint ventures; earnings per share were USD 0.24. Operating income rose 8%. Management continues to focus on recurring revenues and expects initial sales from the Pigeon Creek project in early 2027. After-hours, the stock fell 3.22% to USD 66.81. » More on de.investing.com